Please assess the completion status of the following clinical trial:

Trial Title: Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe NS, defined as proteinuria exceeding 3.5 g/24h or 50 mg/kg/24h and serum albumin ≤2.5 g/dL;~* eGFR ≥30 mL/min/1.73 m2.~Exclusion Criteria:~* Body mass index (BMI) ≥40 kg/m2;~* Low body mass (\<45 kg for female, \<57 kg for male);~* Acute VTE;~* Previously introduced anticoagulation (due to comorbidities);~* Contraindications for enoxaparin;~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nephrotic syndrome - fixed dose (NS-FD) (Type: EXPERIMENTAL): Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
- Nephrotic syndrome - adjusted dose (NS-AD) (Type: EXPERIMENTAL): Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
- Control - fixed dose (C-FD) (Type: ACTIVE_COMPARATOR): Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).